ES2721098T3 - Compound chromatography compounds - Google Patents

Compound chromatography compounds Download PDF

Info

Publication number
ES2721098T3
ES2721098T3 ES14786355T ES14786355T ES2721098T3 ES 2721098 T3 ES2721098 T3 ES 2721098T3 ES 14786355 T ES14786355 T ES 14786355T ES 14786355 T ES14786355 T ES 14786355T ES 2721098 T3 ES2721098 T3 ES 2721098T3
Authority
ES
Spain
Prior art keywords
substituted
unsubstituted
alkenyl
alkyl
cycloalkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES14786355T
Other languages
Spanish (es)
Inventor
Peter Kumpalume
Oliver Schon
Christine Patricia Donahue
Ghotas Evindar
David I Israel
David Paolella
Letian Kuai
Ninad V Prabhu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Intellectual Property Development Ltd
Original Assignee
GlaxoSmithKline Intellectual Property Development Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GlaxoSmithKline Intellectual Property Development Ltd filed Critical GlaxoSmithKline Intellectual Property Development Ltd
Application granted granted Critical
Publication of ES2721098T3 publication Critical patent/ES2721098T3/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D411/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms
    • C07D411/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen and sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Medicinal Preparation (AREA)

Abstract

Un compuesto de fórmula Ib como se muestra a continuación,**Fórmula** en la que R1 es H, -CI, -F, -Br, -I, -OH, -CN, -NO2, alquilo C1-C6 sustituido o sin sustituir, alquenilo C1-C6 sustituido o sin sustituir, cicloalquilo, arilo o heteroarilo sustituido o sin sustituir; R3 es -[(CH2)2E]n(CH2)2NR'R" y n es cualquier número entero de 0 a 30, en la que R' y R" son cada uno independientemente H, alquilo C1-C6 sustituido o sin sustituir, alquenilo C1-C6 sustituido o sin sustituir o cicloalquilo sustituido o sin sustituir y E es CH2, O, NH o S, o E está ausente; R4 es H, -Cl, -F, -Br, -I, -OH, -CN, -NO2, alquilo C1-C6 sustituido o sin sustituir, alquenilo C1-C6 sustituido o sin sustituir, cicloalquilo, arilo o heteroarilo sustituido o sin sustituir; Y1 e Y3 son independientemente C, O, N, NR2 o S, en la que R2 es H, alquilo C1-C6 sustituido o sin sustituir, alquenilo C1-C6 sustituido o sin sustituir, cicloalquilo, arilo o heteroarilo sustituido o sin sustituir; e Y2 es C o N; o a una sal del mismo.A compound of formula Ib as shown below, ** Formula ** wherein R1 is H, -CI, -F, -Br, -I, -OH, -CN, -NO2, substituted C1-C6 alkyl or unsubstituted, substituted or unsubstituted C1-C6 alkenyl, substituted or unsubstituted cycloalkyl, aryl, or heteroaryl; R3 is - [(CH2) 2E] n (CH2) 2NR'R "and n is any integer from 0 to 30, where R 'and R" are each independently H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkenyl or substituted or unsubstituted cycloalkyl and E is CH2, O, NH or S, or E is absent; R4 is H, -Cl, -F, -Br, -I, -OH, -CN, -NO2, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkenyl, substituted cycloalkyl, aryl or heteroaryl or unsubstituted; Y1 and Y3 are independently C, O, N, NR2, or S, wherein R2 is H, substituted or unsubstituted C1-C6 alkyl, substituted or unsubstituted C1-C6 alkenyl, substituted or unsubstituted cycloalkyl, aryl, or heteroaryl; and Y2 is C or N; or a salt of it.

ES14786355T 2013-10-01 2014-10-01 Compound chromatography compounds Active ES2721098T3 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361885146P 2013-10-01 2013-10-01
US201462025994P 2014-07-17 2014-07-17
PCT/IB2014/064998 WO2015049651A1 (en) 2013-10-01 2014-10-01 Compounds for affinity chromatography and for extending the half-life of a therapeutic agent

Publications (1)

Publication Number Publication Date
ES2721098T3 true ES2721098T3 (en) 2019-07-26

Family

ID=51743521

Family Applications (1)

Application Number Title Priority Date Filing Date
ES14786355T Active ES2721098T3 (en) 2013-10-01 2014-10-01 Compound chromatography compounds

Country Status (12)

Country Link
US (2) US9809558B2 (en)
EP (1) EP3052483B1 (en)
JP (1) JP2016534984A (en)
KR (1) KR20160060660A (en)
CN (1) CN105593222B (en)
AU (1) AU2014330781B2 (en)
BR (1) BR112016007371A2 (en)
CA (1) CA2925862A1 (en)
ES (1) ES2721098T3 (en)
RU (1) RU2016117052A (en)
SG (1) SG11201601870VA (en)
WO (1) WO2015049651A1 (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10697982B2 (en) 2015-09-08 2020-06-30 Merck Patent Gmbh Methods of evaluating quality of a chromatography media which binds anti-A or anti-B antibodies
US20170066839A1 (en) * 2015-09-08 2017-03-09 Merck Patent Gmbh Novel affinity chromatography media for removal of anti-a and/or anti-b antibodies
US10697983B2 (en) 2015-09-08 2020-06-30 Merck Patent Gmbh Methods of evaluating quality of media suitable for removing anti-A or anti-B antibodies
WO2018181738A1 (en) * 2017-03-30 2018-10-04 日立化成株式会社 Separation material
EP3901173A4 (en) 2018-12-21 2022-11-23 Jiangsu Hengrui Medicine Co., Ltd. Bispecific protein
CA3164134A1 (en) 2019-12-06 2021-06-10 Vertex Pharmaceuticals Incorporated Substituted tetrahydrofurans as modulators of sodium channels
UY39800A (en) 2021-06-04 2023-01-31 Vertex Pharma N–(HYDROXYALKYL (HETERO)ARYL) TETRAHYDROFURAN CARBOXAMIDES AS SODIUM CHANNEL MODULATORS

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH187973A4 (en) * 1973-02-09 1977-03-31 Hoechst Ag Process for the optical brightening of textile materials
US4722896A (en) 1981-01-26 1988-02-02 The Beth Israel Hospital Association Method for affinity purification of hybridoma antibodies
US5849874A (en) 1991-07-12 1998-12-15 Gist-Brocades, N.V. Process for the purification of serum albumin
JP2825755B2 (en) * 1993-04-07 1998-11-18 大塚製薬株式会社 Peripheral vasodilator containing piperidine derivative as active ingredient and novel piperidine derivative
CA2182731A1 (en) * 1994-02-03 1995-08-10 Michael P. Vitek Compositions and methods for advanced glycosylation endproduct-mediated modulation of amyloidosis
GB9914825D0 (en) * 1999-06-24 1999-08-25 Smithkline Beecham Spa Novel compounds
AU763356C (en) 1999-12-27 2004-08-26 Japan Tobacco Inc. Fused-ring compounds and use thereof as drugs
DE10139416A1 (en) * 2001-08-17 2003-03-06 Aventis Pharma Gmbh Aminoalkyl substituted aromatic bicycles, process for their preparation and their use as medicaments
CA2481334A1 (en) 2002-04-01 2003-10-16 Anthony C. Stevens Tissue-specific endothelial membrane proteins
ATE425753T1 (en) * 2002-08-02 2009-04-15 Genesoft Pharmaceuticals Inc BIARYL COMPOUNDS WITH ANTI-INFECTIVE ACTION
US7777051B2 (en) 2003-05-13 2010-08-17 Icagen, Inc. Asymmetric benzimidazoles and related compounds as potassium channel modulators
WO2007056155A1 (en) 2005-11-03 2007-05-18 Chembridge Research Laboratories, Inc. Heterocyclic compounds as tyrosine kinase modulators
NZ597960A (en) 2009-07-31 2013-07-26 Ascendis Pharma As Biodegradable polyethylene glycol based water-insoluble hydrogels
WO2011048018A1 (en) * 2009-10-19 2011-04-28 Boehringer Ingelheim International Gmbh Cyclopentanecarboxamide derivatives, medicaments containing such compounds and their use
KR102008946B1 (en) * 2010-08-03 2019-08-08 노브알리스 도이칠란트 게엠베하 LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY
WO2012020080A2 (en) 2010-08-12 2012-02-16 Graffinity Pharmaceuticals Gmbh LIGANDS FOR ANTIBODY AND Fc-FUSION PROTEIN PURIFICATION BY AFFINITY CHROMATOGRAPHY II
WO2012140647A2 (en) 2011-04-11 2012-10-18 Yeda Research And Development Co. Ltd Albumin binding probes and drug conjugates thereof
UA115576C2 (en) 2012-12-06 2017-11-27 Байєр Фарма Акцієнгезелльшафт BENZIMIDASOL DERIVATIVES AS ER4 ANGAGONES
EP2752426A1 (en) 2013-01-03 2014-07-09 Covagen AG Human serum albumin binding compounds and fusion proteins thereof

Also Published As

Publication number Publication date
AU2014330781B2 (en) 2017-05-04
US20160221962A1 (en) 2016-08-04
BR112016007371A2 (en) 2017-08-01
KR20160060660A (en) 2016-05-30
EP3052483B1 (en) 2019-02-06
CA2925862A1 (en) 2015-04-09
SG11201601870VA (en) 2016-04-28
US9809558B2 (en) 2017-11-07
WO2015049651A1 (en) 2015-04-09
EP3052483A1 (en) 2016-08-10
CN105593222B (en) 2018-02-09
RU2016117052A (en) 2017-11-10
CN105593222A (en) 2016-05-18
US9938243B2 (en) 2018-04-10
RU2016117052A3 (en) 2018-06-27
JP2016534984A (en) 2016-11-10
US20170369448A1 (en) 2017-12-28
AU2014330781A1 (en) 2016-04-07

Similar Documents

Publication Publication Date Title
ES2721098T3 (en) Compound chromatography compounds
EA201591703A1 (en) SUBSTITUTED 2-ABABILITIES AND THEIR APPLICATION AS OREXIN RECEPTOR MODULATORS
CY1120188T1 (en) NAPHYTHRIDINE PRODUCERS USEFUL AS INTEGRINE COMPONENTS avv6
PE20160523A1 (en) DERIVATIVES OF ARYL OR HETEROARYL AS INHIBITORS OF SMALL MOLECULES OF FIBROSIS
CO7400871A2 (en) Heteroaryl substituted pyridyl compounds useful as kinase modulators
ECSP11010912A (en) PIRROL COMPOUNDS
EA201590979A1 (en) METHODS AND INTERMEDIATE CHEMICAL COMPOUNDS TO OBTAIN PHARMACEUTICAL MEANS
UA111626C2 (en) DIGIDROCHINOLIN-2-ON DERIVATIVES
EA201690019A1 (en) AMINOTRIASIN DERIVATIVE AND CONTAINING ITS PHARMACEUTICAL COMPOSITION
PE20151779A1 (en) SUBSTITUTED XANTHINES AND METHODS OF USE OF THEM
AR093184A1 (en) PIRIMIDINE COMPOSITE REPLACED AS AN INHIBITOR OF QUINURENINA-3-MONOOXIGENASA AND PHARMACEUTICAL COMPOSITION THAT UNDERSTAND IT
AR080057A1 (en) PIRIDINES DISUSTITUTED AS ANTI-BANERIGENS
BR112013018732A2 (en) new aryl benzocycloalkyl amide derivatives
CO2017001178A2 (en) Derivative of pyridone having a tetrahydropyranyl methyl group
EA201691031A1 (en) SYNTHESIS OF MACROCYCLIC TRIPEPTIDE INHIBITING HCV NS3
CY1117688T1 (en) Tetrahydropyrrolothiazine compounds
PE20150598A1 (en) N-PROP-2-INYL CARBOXAMIDE DERIVATIVES AND THEIR USE AS ANTAGONISTS OF THE POTENTIAL TRANSIENT RECEPTOR OF SUBFAMILY A, MEMBER 1
RS53909B1 (en) 5-(phenyl/pyridinyl-ethinyl)-2-pyridine/2-pyrimidine-carborxamides as mglur5 modulators
EA201391267A1 (en) METHOD OF OBTAINING ORGANIC COMPOUNDS
CR20160082A (en) NEW DERIVATIVE OF TRIAZINA
BR112013005823B8 (en) HETEROCYCLIC COMPOUNDS FOR THE TREATMENT OR PREVENTION OF DISORDERS CAUSED BY REDUCED NEUROTRANSMISSION OF SEROTONIN, NOREFNEPHRINE OR DOPAMINE
SA519400868B1 (en) Heteroaromatic modulators of the retinoid-related ‎orphan receptor gamma
EA201491105A1 (en) CYCLIC URINE DERIVATIVES AS ANTAGONISTS OF ANDROGEN RECEPTORS
PE20141168A1 (en) DERIVATIVES OF PYRAZOLIDIN-3-ONA
NI201200039A (en) NEW DIHYDRO DERIVATIVES - OXAZOLOBENZODIAZEPINONES, THEIR PROCEDURE